Bristol Myers Squibb Expands Camzyos Data in oHCM, Targeting Adolescent Patients
Event summary
- Bristol Myers Squibb presented new clinical and real-world data for Camzyos (mavacamten) at the American College of Cardiology’s Annual Scientific Session & Expo 2026 (ACC.26).
- Data includes results from the SCOUT-HCM Phase 3 trial, evaluating Camzyos in adolescents with obstructive hypertrophic cardiomyopathy (oHCM).
- Real-world studies (DISCOVER-HCM, MARVEL-HCM, COMPASS-HCM) showed consistent effectiveness and safety of Camzyos across diverse patient populations.
- Camzyos is approved in over 60 countries and prescribed to more than 22,000 patients in the U.S. alone.
The big picture
Bristol Myers Squibb is reinforcing its leadership in the treatment of obstructive hypertrophic cardiomyopathy (oHCM) with new data on Camzyos, particularly in adolescent patients. The company is leveraging real-world evidence to expand the therapeutic reach of its cardiac myosin inhibitor, addressing a critical unmet need in a rare disease space. The strategic focus on broadening patient access and outcomes aligns with broader industry trends toward precision medicine and targeted therapies in cardiovascular disease.
What we're watching
- Regulatory Expansion
- Whether Bristol Myers Squibb can secure regulatory approval for Camzyos in adolescent oHCM patients, expanding its market potential.
- Competitive Positioning
- How the new data will solidify Bristol Myers Squibb’s leadership in the cardiac myosin inhibitor (CMI) class.
- Real-World Adoption
- The pace at which real-world evidence will drive broader adoption of Camzyos in diverse patient populations.
Related topics